Filamentous bacteriophage delays healing of Pseudomonas-infected wounds

Highlights

- Pf, a bacteriophage produced by *Pseudomonas aeruginosa*, delays chronic wound healing
- Pf impairs re-epithelization and barrier integrity in animal wound models
- Pf inhibits keratinocyte signaling of CXCL1, contributing to impaired cell migration
- Pf is associated with delayed healing in patients with chronic wound infections

In brief

Wounds chronically infected by *P. aeruginosa* are characterized by poor healing and progression of disease. Bach et al. report that Pf, a bacteriophage expressed by *P. aeruginosa*, impedes healing by directly inhibiting keratinocyte chemokine expression migration, resulting in impaired wound re-epithelialization.
Filamentous bacteriophage delays healing of Pseudomonas-infected wounds

Michelle S. Bach,1,2,11 Christiaan R. de Vries,1,11 Arya Khosravi,1,11 Johanna M. Sweere,1,2 Medeea C. Popescu,1,2 Qingquan Chen,1 Sally Demirdjian,1 Aviv Hargil,1 Jonas D. Van Belleghem,1 Gernot Kaber,1 Maryam Hajfathalian,1,3 Elizabeth B. Burgener,1 Dan Liu,1 Quynh-Lam Tran,1 Tejas Dharmaraj,1,2 Maria Birukova,1,2 Vivekananda Sunkari,1,2 Swathi Balaji,1 Nandini Ghosh,1 Shomita S. Mathew-Steiner,1 Mohamed S. El Masry,1 Sundeep G. Keswani,5 Niaz Banaei,1,6 Laurence Nedelec,1 Chandan K. Sen,7 Venita Chandra,8 Patrick R. Secor,9 Gina A. Suh,10,12 and Paul L. Bollyky1,12,13,14,1*

1Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA
2Stanford Immunology, Stanford University, Stanford, CA 94305, USA
3Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
4Center for Excellence in Pulmonary Biology, Department of Pediatrics, Stanford University, Stanford, CA 94305, USA
5Division of Pediatric Surgery, Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
6Division of Pathology, Department of Medicine, Stanford University, Stanford, CA 94305, USA
7Department of Surgery, Indiana University, Indianapolis, IN 46202, USA
8Department of Surgery, Division of Vascular Surgery, Stanford University, Stanford, CA 94305, USA
9Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA
10Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA
11These authors contributed equally
12Senior author
13Twitter: @bollyky
14Lead contact
*Correspondence: pbollyky@stanford.edu
https://doi.org/10.1016/j.xcrm.2022.100656

SUMMARY

Chronic wounds infected by Pseudomonas aeruginosa (Pa) are characterized by disease progression and increased mortality. We reveal Pf, a bacteriophage produced by Pa that delays healing of chronically infected wounds in human subjects and animal models of disease. Interestingly, impairment of wound closure by Pf is independent of its effects on Pa pathogenesis. Rather, Pf impedes keratinocyte migration, which is essential for wound healing, through direct inhibition of CXCL1 signaling. In support of these findings, a prospective cohort study of 36 human patients with chronic Pa wound infections reveals that wounds infected with Pf-positive strains of Pa are more likely to progress in size compared with wounds infected with Pf-negative strains. Together, these data implicate Pf phage in the delayed wound healing associated with Pa infection through direct manipulation of mammalian cells. These findings suggest Pf may have potential as a biomarker and therapeutic target in chronic wounds.

INTRODUCTION

Chronic wounds are associated with extensive human suffering and massive economic costs.1,2 Over 6.5 million Americans have chronic wounds, and their care is estimated to cost 25 billion dollars annually.2 Bacterial infections frequently complicate chronic wounds, leading to delayed wound healing,3 increased rates of amputation,4 and extensive morbidity and mortality.5–7

Wounds infected with the Gram-negative pathogen Pseudomonas aeruginosa (Pa) are characterized by poor outcomes.3–11 Pa is prevalent in infections of burns,12 diabetic ulcers, and postsurgical sites.13 The presence of Pa is associated with delayed wound closure in both humans as well as animal models,3,14–16 and wounds infected with Pa tend to be larger than those in which Pa is not detected.17,18 This wound chronicity is associated with ineffective bacterial clearance19 and delayed healing.20

In addition to wound infections, Pa is a major human pathogen in other contexts14,19,21 due to increased antibiotic resistance incidence. In recognition of the magnitude of this problem, Pa is deemed a priority pathogen by the World Health Organization (WHO) and the Centers for Disease Control (CDC).22 Therefore, there is great interest in identifying novel biomarkers, virulence factors, and therapeutic targets associated with Pa infections. One such potential target is Pf bacteriophage (Pf phage), a filamentous virus produced by Pa.8,11,23 Unlike lytic bacteriophages used in phage therapy,24,25 Pf typically does not lyse its bacterial hosts. Instead, Pf phage integrates into the bacterial chromosome as prophage and can be produced without destroying their bacterial hosts.26,27 Indeed, the production of phage virions is partially under bacterial control.28 We and others have reported that Pf phages promote Pa fitness by serving as structural elements in Pa biofilms29,30 and contributing to bacterial
phenotypes associated with chronic Pa infection, including bacterial aggregation and reduced motility. Pf phages also impact host immunity in ways that promote chronic infection. We recently reported that Pf phages directly alter cytokine production and decrease phagocytosis by macrophages. These effects were associated with Pa strains that produced Pf phage (Pf+) strains were more likely than strains that do not produce Pf (Pf--) strains to establish wound infections in mice. These and other studies implicate Pf phage as a virulence factor in Pa infections.  

We hypothesized that Pf phage might contribute to the delayed wound healing associated with Pa wound infections. To test this, we first examined the effects of Pf phage on wound healing and barrier function in an in vivo mouse and pig models. We then investigated the mechanism by which Pf phage inhibits wound healing in a well-established in vitro model (keratinocyte scratch assay). Finally, we examined the association between Pf phage and delayed wound healing in a cohort of 36 patients seen at the Stanford Advanced Wound Care Center.

**RESULTS**

**Infection with a Pf(+) strain of Pa causes worse morbidity in a murine chronic-wound infection model**

We first examined the impact of a Pf(+) strain of Pa (PAO1) compared with a Pf(-) isogenic strain (PAO1ΔPf4) on morbidity and mortality in a delayed inoculation murine wound infection model. We previously pioneered this model to study the initial establishment of Pa wound infections in otherwise healthy C57BL/6 mice in the absence of foreign material, diabetes, or other forms of immune suppression. Here, we have adapted this model to study wound healing in the setting of infection over a 2-week time period. In brief, we generated bilateral, full-thickness excisional wounds on the dorsum of mice. These wounds were then inoculated 24 h later with 4 × 10⁵/mL PAO1, PAO1ΔPf4, or PBS as a control. We then assessed wound size daily through day 13 post-Pa inoculation (day 14 post-wounding). A schematic of this protocol is shown in Figure 1A.

All mice survived the 14-day experiment (Figure S1), and all wounds were infected on day 3 (Figure 1B), regardless of whether they received PAO1 or PAO1ΔPf4. However, by day 13, wounds in the PAO1 group remained inflamed and purulent. In contrast, PAO1ΔPf4 wounds were largely healed (Figure 1B). Moreover, mice inoculated with PAO1 lost significant weight compared with mice that received PAO1ΔPf4 or PBS (Figure 1C). These data confirm Pf phage contributes to worse morbidity in this chronic-wound model, consistent with prior studies showing Pf promotes Pa pathogenesis.

**Pf4 phages delay wound healing**

We next examined the effect of Pf4, the phage present in PAO1, on wound healing in our in vivo model. Healing was defined as the remaining open wound area as a fraction of the original wound area. Inoculation with PAO1ΔPf4 led to significantly improved wound healing over time compared with infection with PAO1. Indeed, wound healing in many of the mice inoculated with PAO1 plateaued by day 7 (Figure 1D). By day 13, most of the mice from the PAO1ΔPf4 group resolved their infections and healed their wounds completely, whereas most wounds infected with PAO1 persisted (Figure 1E). Similar results were observed when area under the curve (AUC), a measure of cumulative change in wound area, was evaluated (Figure 1F). We then examined wound histology from tissue sections collected on day 13 post-wounding that were collected from these mice. We observed that uninfected wounds and wounds infected with PAO1ΔPf4 exhibited healthy granulation tissue (Figures 1G and 1H), whereas wounds infected with PAO1 had substantial necrotic debris, minimal granulation tissue, and obvious infection (Figure 1I). When the epithelial gap was measured, wounds infected with PAO1 were found to have significantly less re-epithelialization by day 13 compared with PAO1ΔPf4 (Figure 1J).

Taken together, these data indicate that the production of Pf4 phage by PAO1 is associated with increased morbidity, impaired wound healing, and delayed re-epithelialization in this model.

**Pf4 phages delay re-epithelialization in the absence of bacterial infection**

Because the aforementioned data were collected in the setting of infection, it is difficult to distinguish wound persistence is due to phage-enhanced Pa pathogenesis or from a direct inhibition on wound healing by Pf. To elaborate whether Pf directly impairs wound healing, we treated mice with purified Pf4 phage in the absence of bacterial infection. In particular, we administered heat-killed PAO1 (HK-Pa) or PBS to C57BL6 mice 1 day after wounding in the absence or presence of supplemental Pf4 phage. Day 7 rather than day 13 was used in the studies, as wounds healed more rapidly in the absence of live bacterial infections. In addition, wounds were splinted with a silicone ring to prevent healing via contraction, which otherwise happens in mice in the absence of infection. A schematic detailing this protocol is shown in Figure S2A. Both the wound area on day 1 (Figure S2B) and the epithelial gap on day 7 post-wounding (Figure S2C) were assessed morphometrically. Representative area demarcations are shown inset into these images.

We observed that supplementation with Pf4 phage is associated with a larger epithelial gap on day 7 when normalized to day 1 wound area (Figure S2D), consistent with direct inhibition of wound healing by Pf4. Further, overall inflammatory cell counts are not altered by Pf phage supplementation (Figures S2E–S2G). We conclude that Pf reduces re-epithelialization of murine wounds in the absence of infection. These studies indicate that Pf4 phage directly antagonizes wound healing.

**Pf phage inhibits re-epithelialization in a pig wound model**

To better understand the impact of Pf4 phage on re-epithelialization, we next examined whether Pf phage alters healing in a porcine burn-wound model. Pig skin is anatomically and physiologically more similar to human skin, relative to rodents. Further, while mice largely rely on contraction for wound closure, both pigs and humans heal partial thickness wounds through re-epithelialization. As such, the porcine wound model has been suggested to more closely mimic human disease and serve as a preferred preclinical model. Here, eight domestic white
pigs were wounded according to previously established protocols.41,42 Each pig received eight dorsal burn wounds, which were then inoculated 3 days later with PAO1 or PAO1ΔPf4 (Figure 2A). At indicated times, images were taken of wounds (Figure 2B) and tissue healing was assessed by digital planimetry (Figures 2B and 2C). In this model, Pf4 does not delay wound healing, as determined by morphometric measurement over time (Figure 2C). The limited inflammatory change noted in Pa-infected pig wounds (Figure 2B), relative to mice (Figure 1B), may account for these disparate results between these two animal-model systems. Further, visual wound area measurements do not account for functional wound healing, including re-establishing epithelial barrier integrity.43

While gross morphological differences in wound healing were not appreciated, burn wounds infected with PAO1 revealed decreased expression of keratin 14, a marker expressed in mitotically active basal epithelial cells and is associated with protection against mechanical stress (Figures S3A and S3B).44,45 Further, wounds infected with PAO1 demonstrated reduced keratinocyte proliferation compared with PAO1ΔPf4 (Figures 3C and 3D). These studies indicate that infection with Pf4 results in defects in wound healing and barrier integrity. To further assess skin barrier function following Pf4 infection, trans-epidermal water loss (TEWL) studies were performed on wounds at indicated times (Figure 2A). TEWL is a validated, objective, and highly sensitive assessment of skin integrity and wound re-epithelization.41,42 While wounds infected with PAO1ΔPf4 recover barrier function over time and approach that of healthy skin, PAO1-infected wounds, despite apparent wound closure (Figures 2B and 2C), demonstrate persistent water vapor loss consistent with barrier dysfunction (Figure 2D). These studies reveal persistent barrier dysfunction in Pf4-infected wounds, indicating that Pf phage compromises wound re-epithelization.

**Pf4 phages impair in vitro keratinocyte migration**

The TEWL studies reveal impaired barrier integrity in Pf4-infected wounds, consistent with defects in re-epithelization. Because re-epithelialization is mediated by keratinocytes, these findings
suggest Pf4 may influence keratinocyte proliferation and/or migration. Direct stimulation of keratinocytes and fibroblasts with Pf4 does not alter cell viability or proliferation (Figure S4). We then assessed whether Pf4 inhibits keratinocytes cell migration. Direct stimulation of keratinocytes and fibroblasts with Pf4 does not alter cell viability or proliferation (Figure S4). A schematic of this protocol is shown (Figure 3A). We demonstrate that treatment of HaCaT keratinocytes with purified Pf4 phage impairs cell migration relative to controls (Figures 3B and 3C). These effects were most pronounced in the setting of bacterial lipopolysaccharide (LPS), a component of the bacterial outer membrane that can be expected to be present wherever Pf phages are expressed by bacteria. These data suggest Pf4 phages directly antagonize keratinocyte migration in response to inflammatory signals associated with bacteria.

Our previous studies revealed that Pf4 phage suppresses production of tumor necrosis factor alpha (TNFα) and other cytokines made in response to LPS by macrophages and monocytes. To investigate whether Pf4 alters expression of cytokines and chemokines by keratinocytes, we performed a Luminex assay on HaCaT keratinocytes treated with Pf4 phage. While Pf4 does not alter expression of the majority of cytokines and chemokines tested, select inhibition was noted of CXCL1, CCL7, and CCL22, relative to LPS-treated cells (Figures 3D–3F). These data argue Pf4 actively suppresses keratinocyte-derived chemokine production during inflammatory challenge and may contribute to diminished keratinocyte migration and wound re-epithelialization.

While CCL7 and CCL22 appear to primarily recruit monocytes and lymphocytes, CXCL1 has been described to promote keratinocyte migration. To determine whether Pf4-mediated CXCL1 inhibition impedes keratinocyte migration, CXCL1 or vehicle control was supplemented to keratinocytes in addition to Pf4, LPS, or mock treatment (Figure 3G). Exogenous CXCL1 did not confer additive effects to LPS treatment, which is consistent with elevated endogenous expression of this chemokine in this treatment group (Figure 3H). Together, these data indicate that Pf4 phages directly target keratinocytes and inhibit chemokine expression during inflammatory stress to limit cell migration.

**Pf phages are abundant in human wounds infected with *Pa***

In light of the decreased wound healing observed in the presence of Pf4 phage in our *in vivo* model, we investigated the clinical impact of Pf phage on human chronic *Pa* wound infections. A total of 113 patients referred to the infectious disease service at the Stanford Advanced Wound Care Center (AWCC) were enrolled from June 2016 to June 2018. Our protocol for screening and classifying these patients is described in Figure S5. Three *Pa*-positive patients (one who was Pf(+)) and two who were Pf(−) were excluded from the final analysis due to amputation, exposed bone or tendon, or loss to follow-up (Figure S5). Patient characteristics are described in Table S1, and microbiological qualities of the *Pa*-positive wound isolates are described in Table S2.

Of the *Pa*-positive patients included in our analysis, Pf prophage (integrated into the bacterial chromosome) was detected in 69% (25/36) of the wounds (Table S1). Pf phage levels ranged from $3.55 \times 10^8$ copies/swab, with a mean of $108 \text{CFU}$. Of 113 patients referred to the infectious disease service at the Stanford Advanced Wound Care Center (AWCC) were enrolled from June 2016 to June 2018. Our protocol for screening and classifying these patients is described in Figure S5. Three *Pa*-positive patients (one who was Pf(+)) and two who were Pf(−) were excluded from the final analysis due to amputation, exposed bone or tendon, or loss to follow-up (Figure S5). Patient characteristics are described in Table S1, and microbiological qualities of the *Pa*-positive wound isolates are described in Table S2.

Of the *Pa*-positive patients included in our analysis, Pf prophage (integrated into the bacterial chromosome) was detected in 69% (25/36) of the wounds (Table S1). Pf phage levels ranged from $3.55 \times 10^8$ copies/swab, with a mean of $108 \text{CFU}$. Patient characteristics are described in Table S1, and microbiological qualities of the *Pa*-positive wound isolates are described in Table S2.
Figure 3. Pf phage impedes keratinocyte migration

(A) Schematic of HaCaT keratinocyte-migration assays.
(B) Representative images of keratinocyte migration at 0 and 48 h following treatment with mock, Pf, LPS, or Pf + LPS.
(C) Effect of Pf (1 × 10^10 copy no./mL) and LPS (1 μg/mL) on HaCaT keratinocyte migration, presented as area at 48 h/area at 0 h with decreased area correlating with increased cell migration. Three biological replicates per experiment are shown. Results are representative of three independent experiments. Statistics are by one-way ANOVA.

(D) Heatmaps from Luminex immunoassay performed on supernatant from HaCaT keratinocytes stimulated with Pf and LPS at 48 h. Results are presented as log 2-fold change of concentration compared with PBS control.

(E and F) Interpolated values (pg/mL) of select cytokines and growth factors from Luminex assay of human primary monocytes stimulated with Pf and LPS for 24 h (E) or 48 h (F) are shown. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way ANOVA. ns, not significant.

(G) Schematic of keratinocyte migration assays with pretreatment with CXCL1, Pf, and/or LPS.

(H) Effect of CXCL1 supplementation (1 μg/mL) on HaCaT keratinocyte migration, presented as area at 48 h/area at 0 h with decreased area correlating with increased cell migration. Three biological replicates per experiment are shown. Results are representative of three independent experiments. *p < 0.05 and **p < 0.01 by unpaired Student’s t test.
2.16 × 10^7 copies/swab in Pf(+) samples. Subjects in the Pf(−) subset were older compared with the Pf(+) subset (61.6 ± 14.7 versus 76.6 ± 14.5; p = 0.008; Table S1). Higher numbers of Pf(+) patients were on antimicrobial treatments compared with Pf(−) patients, though this was not statistically significant (Table S2). There were no significant correlations between Pf phage status and gender, BMI, recurrence of infection, race or ethnicity, comorbidities, antimicrobial resistance, or co-infection with other bacterial or fungal species (Table S1). This excludes co-infection as a confounding variable. These data indicate that Pf phages are prevalent and highly abundant in chronic wounds in this cohort.

**Pf phages are associated with wound progression**

To test whether Pf phages inhibit wound healing, we followed this cohort over time for a period of 2 years. We had previously reported in a cross-sectional cohort study of these same patients that wounds infected with Pf(+) strains of Pa were significantly older at the time of enrollment than Pf(−) strains.33 We now asked in a prospective cohort study whether wounds infected with Pf(+) Pa strains versus Pf(−) Pa strains healed over time. A survival analysis using the endpoint of wound closure showed a significant difference between time to wound closure of the Pf(+) wounds versus Pf(−) wounds (Figure 4A). We further measured changes in wound dimensions over time in the 36 Pa-positive patients, starting with measurements taken at the patient’s initial clinic visit. We found that Pf(+) patients were more likely to experience an increase in wound size over time than patients who were Pf(−) (8/25 versus 0/11, respectively) (Figures 4B and 4C). We observed that all wounds that grew in size over the study period were Pf(+) (Figure 4C). Together, these data indicate that Pf(+) strains of Pa are associated with delayed wound healing.

**DISCUSSION**

We report that Pf phage impairs wound healing in mice, pigs, and humans. In mice, Pf phage delays healing in both the presence and absence of live Pa, indicative that effects on wound healing are independent of Pf influence on Pa pathogenesis. In pigs, wound infection with a Pf(+) strain of Pa resulted in impaired epithelial barrier integrity. Further, in a prospective cohort study in humans, Pf phage is associated with delayed wound healing and wound size progression. Together, these data strongly implicate Pf phage in delayed wound healing.

These effects of Pf phage on delayed healing are associated with altered keratinocyte chemokine expression and impaired re-epithelialization. In particular, keratinocyte secretion of CXCL1 secretion is inhibited by Pf4 in the setting of inflammatory stress. Re-epithelialization is critical for wound closure, and its failure leaves wounds vulnerable to reinjury, re-infection, and perpetuation.48–50 Our data are consistent with reports that Pa infections can cause impaired epithelialization,42 although this was not previously attributed to Pf phage.

These studies align well with but are distinct from our earlier reports on Pf phages promoting chronic infection. In those studies, we reported that Pf phage inhibits bacterial clearance through effects on phagocytosis and TNF production, contributing to the establishment of chronic wound infections.33 We likewise reported that Pf promotes chronic lung infections.34 The data presented here indicate that, in tandem with inhibiting antimicrobial immunity, Pf phages also impair wound re-epithelialization.

This work reveals bacteriophages directly modulate mammalian cells to promote disease. We conclude that Pf phages may serve as a biomarker and therapeutic target for the delayed wound healing that occurs in the context of Pa wound infections. This finding may have particular relevance, given our recent report that a vaccine targeting Pf could prevent initial Pa wound infection.33 Future longitudinal studies in independent cohorts are needed to validate these studies.

**Limitations of the study**

Limitations of this work include that our prospective cohort study is small in size (36 patients). It will be important to validate these findings in larger, independent cohorts. It will also be important to validate these findings with Pf(+) and Pf(−) Pa clinical isolates, as currently, only lab strains were examined in our preclinical models. Further, our data demonstrating that Pf impairs keratinocyte migration via inhibition of chemokine signaling do not exclude alternative mechanisms by which Pf promotes chronic wounds. Such alternative mechanisms will include promoting formation of biofilms as well as potential steric hindrance of wound closure due to the anionic potential of Pf filaments.29 Finally, an important limitation of this study is the absence of a CXCL1 knockout in vivo wound model to further validate our findings that Pf inhibits CXCL1 expression to impair wound healing.

**STAR★METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Bacterial strains and culture conditions
  - Cell culture conditions
  - Animal studies
  - Collection of wound swabs from human patients
  - Human wound closure analysis
- METHOD DETAILS
  - Materials and reagents
  - Preparation of heat-killed bacteria
  - Phage purification
  - Quantification of Pf phage
  - In vivo murine full-thickness wound infection model
  - Murine wound healing analysis
  - Porcine full thickness burn wound model
  - Immunohistochemistry
  - Trans-epidermal water loss (TEWL) measurement
  - Migration assay
  - Lactate dehydrogenase and resazurin assays
  - Luminex immunoassay
- QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2022.100656.

ACKNOWLEDGMENTS

M.S.B. was supported by the Stanford Bio-X Fellowship. C.R.d.V. was supported by grant T32 AI007502, Doris Duke Physican Scientist Fellowship, and K08AI151089. A.K. was supported by grant T32 AI007502. J.M.S. was supported by the Gabilian Stanford Graduate Fellowship for Science and Engineering and the Lubert Stryer Bio-X Stanford Interdisciplinary Graduate Fellowship. M.H. was supported by funding from NIH grant 1K99EB028838-01A1. P.L.B. was supported by grants R21AI133370, R21AI133240, and R01AI12492093, and grants from Stanford SPARK, the Falk Medical Research Trust, and the Cystic Fibrosis Foundation (CFF).

AUTHOR CONTRIBUTIONS

M.S.B. and C.R.d.V. contributed to the study design, conducted experiments, acquired and analyzed data, and prepared the manuscript. A.K. conducted experiments, acquired and analyzed data, and revised the manuscript. J.M.S. and M.C.P. provided methods and assisted in conducting experiments, data analysis, and manuscript revisions. Q.C., S.D., J.D.V.B., M.H., D.L., Q.-L.T.,
REFERENCES

1. Järbrink, K., Ni, G., Sönnergren, H., Schmidtchen, A., Pang, C., Bajpai, R., and Carl, J. (2016). Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review. Syst. Rev. 5, 152. https://doi.org/10.1186/s13643-016-0329-y.

2. Kirsner, R.S. (2016). The wound healing society chronic wound ulcer healing guidelines update of the 2006 guidelines - blending old with new. Wound Repair Regen. 24, 110–111. https://doi.org/10.1111/wrr.12393.

3. Guo, S., and DiPietro, L.A. (2010). Factors affecting wound healing. J. Dent. Res. 89, 219–229. https://doi.org/10.1177/0022034509359125.

4. Gardner, S.E., and Frantz, R.A. (2008). Wound bioburden and infection-related complications in diabetic foot ulcers. Biol. Res. Nurs. 10, 44–53. https://doi.org/10.1177/1099800408319056.

5. Bowler, P.G. (2002). Wound pathophysiology, infection and therapeutic options. Ann. Med. 34, 419–427. https://doi.org/10.1080/078538902321012360.

6. Clinton, A., and Carter, T. (2015). Chronic wound biofilms: pathogenesis and potential therapies. Lab. Med. 46, 277–284. https://doi.org/10.1309/lmbswku4udpjrt5o.

7. Sall, C., and Kunimoto, B. (2013). An update on chronic wounds and the role of biofilms. J. Cutan. Med. Surg. 17, 371–376. https://doi.org/10.1097/TCM.0b013e31823102c9.

8. Dowd, S.E., Sun, Y., Secor, P.R., Rhoads, D.D., Wolcott, B.M., James, G.A., and Wolcott, R.D. (2008). Survey of bacterial diversity in chronic wounds using Pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol. 8, 43. https://doi.org/10.1186/1471-2180-8-43.

9. James, G.A., Swooger, E., Wolcott, R., deLanney, P.E., Secor, P., Sestrich, J., Costerton, J.W., and Stewart, P.S. (2008). Biofilms in chronic wounds. Wound Repair Regen. 16, 37–44. https://doi.org/10.1111/j.1524-725x.2007.00321.x.

10. Kirketerp-Møller, K., Jensen, P.O., Fazli, M., Madsen, K.G., Pedersen, J., Moser, C., Tolker-Nielsen, T., Hoiby, N., Givskov, M., and Bjarnsholt, T. (2008). Distribution, organization, and ecology of bacteria in chronic wounds. J. Clin. Microbiol. 46, 2717–2722. https://doi.org/10.1128/jcm.00501-08.

11. Malic, S., Hill, K.E., Hayes, A., Percival, S.L., Thomas, D.W., and Williams, D.W. (2009). Detection and identification of specific bacteria in wound biofilms using peptide nucleic acid fluorescent in situ hybridization (PNA FISH). Microbiol. Read Engl. 155, 2603–2611. https://doi.org/10.1099/mic.0.0287712-0.

12. Tredget, E.E., Shankowsky, H.A., Rennie, R., Burrell, R.E., and Logsetty, S. (2004). Pseudomonas infections in the thermally injured patient. Burns J. Int. Soc. Burn Inj. 30, 3–26. https://doi.org/10.1016/j.burns.2003.08.007.

13. Percival, S.L., Suleman, L., Vuotto, C., and Donelli, G. (2015). Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control. J. Med. Microbiol. 64, 323–334. https://doi.org/10.1099/jmm.0.000332.

14. Bryers, J.D. (2008). Medical biofilms. Biotechnol. Bioeng. 100, 1–18. https://doi.org/10.1002/bit.21838.

15. Watters, C., DeLeon, K., Trivedi, U., Griswold, J.A., Lyte, M., Hampel, K.J., Wargo, M.J., and Rumbaugh, K.P. (2013). Pseudomonas aeruginosa biofilms perturb wound resolution and antibiotic tolerance in diabetic mice. Med. Microbiol. Immunol. 202, 131–141. https://doi.org/10.1007/s00430-012-0277-7.

16. Zhao, G., Usui, M.L., Underwood, R.A., Singh, P.K., James, G.A., Stewart, P.S., Fleckman, P., and Olerud, J.E. (2012). Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model. Wound Repair Regen. 20, 342–352. https://doi.org/10.1111/j.1524-725x.2012.00793.x.

17. Gjødsbøl, K., Christensen, J.J., Karlsmark, T., Jørgensen, B.K., Klein, B.M., and Kroglef, K.A. (2008). Multiple bacterial species reside in chronic wounds: a longitudinal study. Int. Wound J. 3, 225–231. https://doi.org/10.1111/j.1742-481x.2007.00159.x.

18. Jesaitis, A.J., Franklin, M.J., Berglund, D., Sasaki, M., Lord, C.I., Bleazard, J.B., Duffy, J.E., Beyenal, H., and Lewandowski, Z. (2003). Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J. Immunol. 171, 4329–4339. https://doi.org/10.4049/jimmunol.171.8.4329.

19. Sen, C.K., Gordillo, G.M., Roy, S., Kirsner, R., Lambert, L., Hunt, T.K., Gottrup, F., Gurtner, G.C., and Longaker, M.T. (2009). Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 17, 763–771. https://doi.org/10.1111/j.1524-725x.2009.00543.x.

20. Bjarnsholt, T., Kirketerp-Møller, K., Jensen, P.O., Madsen, K.G., Phipps, R., Kroglef, K., Hoiby, N., and Givskov, M. (2008). Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen. 16, 2–10. https://doi.org/10.1111/j.1524-725x.2007.00283.x.

21. Heiby, N., Clouf, O., Johansen, H.K., Song, J., Moser, C., Jensen, P.O., Molin, S., Givskov, M., Tolker-Nielsen, T., and Bjarnsholt, T. (2011). The clinical impact of bacterial biofilms. Int. J. Oral Sci. 3, 55–65. https://doi.org/10.4248/ijos011026.

22. Taccionelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L., Pulcini, C., Kahlmeter, G., Klytmans, J., Carmeli, Y., et al. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327. https://doi.org/10.1016/S1473-3099(17)30753-3.

23. Secor, P.R., Burgeon, E.B., Knippers, M., Jennings, L.K., Roman-Cruz, V., Popescu, M., Van Belleghem, J.D., Haddock, N., Copeland, C., Michaela, L.A., et al. (2020). PI bacteriophages and their impact on Pseudomonas virulence, mammalian immunity, and chronic infections. Front. Immunol. 11, 244. https://doi.org/10.3389/fimmu.2020.00244.

24. Gordillo Altamirano, F.L., and Barr, J.J. (2019). Phage therapy in the post-antibiotic era. Clin. Microbiol. Rev. 32, e00066-18. https://doi.org/10.1128/cmrr.00066-18.

25. Górska, A., Międzybrodziec, R., Węgrzyn, G., Józyczki-Matsyiski, E., Borysowski, J., and Weber-Dąbrowska, B. (2020). Phage therapy: current status and perspectives. Med. Res. Rev. 40, 459–463. https://doi.org/10.1002/med.21593.

26. Rakonjac, J., Bennett, N.J., Spagnuolo, J., Gagic, D., and Russel, M. (2011). Filarial bacteriophage biology: phage display and nanotechnology applications. Curr. Issues Mol. Biol. 13, 51–76.

27. Roux, S., Krupovic, M., Daly, R.A., Borges, A.L., Nayfach, S., Schulz, F., Sharrar, A., Mathews Carmeavel, P.B., Cheng, J.F., Ivanova, N.V., et al. (2019). Cryptic viruses revealed as pervasive in bacteria and archaea...
Castang, S., and Dove, S.L. (2012). Basis for the essentiality of H-NS family members in Pseudomonas aeruginosa. J. Bacteriol. 194, 5101–5109. https://doi.org/10.1128/jb.00932-12.

Secor, P.R., Sweere, J.M., Michaels, L.A., Malkovsky, A.V., Lazzaretti, D., Katznelson, E., Rajadas, J., Birmbaum, A., Arrigoni, A., Braun, K., et al. (2015). Filamentous bacteriophage promote biofilm assembly and function. Cell Host Microbe 18, 549–559. https://doi.org/10.1016/j.chom.2015.10.013.

Tarafder, A.K., von Kugelgen, A., Mellul, A.J., Schulze, U., Aarts, D.G.A.L., and Bharat, T.A.M. (2020). Filamentous bacteriophage produced by Pseudomonas aeruginosa alters across Earth’s biomes. Nat. Microbiol. 4, 1895–1906. https://doi.org/10.1038/s41564-019-0105-x.

Sullivan, T.P., Eaglstein, W.H., Davis, S.C., and Mertz, P. (2001). The pig as a model for human wound healing. Wound Repair Regen. 9, 271–279. https://doi.org/10.1111/j.1524-475x.2001.00066.x.

Grillo, H.C., Watts, G.T., and Gross, J. (1958). Studies in wound healing: I. Contraction and the wound contents. Ann. Surg. 148, 145–152. https://doi.org/10.1097/00000658-195808000-00001.

Gordillo, G.M., Bernatchez, S.F., Diegelmann, R., Di Pietro, L.A., Eriksson, E., Hinz, B., Hopf, H.W., Kirsner, R., Liu, P., Parnell, L.K., et al. (2013). Preclinical models of wound healing: is man the model? Proceedings of the wound healing society symposium. Adv. Wound Care 2, 1–4. https://doi.org/10.1089/wound.2012.0367.

Bariki, K.G., Das, A., Dixith, S., Ghatak, P.D., Mathew-Steiner, S., Schwab, E., Khanna, S., Wozniak, D.J., Roy, S., and Sen, C.K. (2019). Electric field based dressing disrupts mixed-species bacterial biofilm infection and restores functional wound healing. Ann. Surg. 269, 756–766. https://doi.org/10.1097/sla.0000000000002504.

Roy, S., Elgharably, H., Sinha, M., Ganesh, K., Chaney, S., Mann, E., Miller, C., Khanna, S., Bergdall, U.K., Powell, H.M., et al. (2014). Mixed-species biofilm compromises wound healing by disrupting epidermal barrier function. J. Pathol. 233, 331–343. https://doi.org/10.1002/path.4360.

Wirkramayake, T.C., Stojadinovic, O., and Tomic-Canic, M. (2014). Epidermal differentiation in barrier maintenance and wound healing. Adv. Wound Care 3, 272–280. https://doi.org/10.1089/wound.2013.0503.

Aliam, H., Sehgal, L., Kundu, S.T., Dalal, S.N., and Vaidya, M.M. (2011). Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. Mol. Biol. Cell 22, 4068–4078. https://doi.org/10.1091/mbc.e10-08-0703.

Rugg, E.L., McLean, W.H., Lane, E.B., Pitera, R., McMillan, J.R., Dopping-Hepenstal, P.J., Navsaria, H.A., Leigh, I.M., and Eady, R.A. (1994). A functional ‘knockout’ of human keratin 14. Genes Dev. 8, 2563–2573. https://doi.org/10.1101/gad.8.21.2563.

Liang, C.-C., Park, A.Y., and Guan, J.-L. (2007). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329–333. https://doi.org/10.1038/nprot.2007.30.

Kroeze, K.L., Boinik, M.A., Sampat-Sardjoeperasrd, S.C., Waaivjna, T., Scheper, R.J., and Gibbs, S. (2012). Autocrine regulation of re-epithelialization after wounding by chemokine receptors CCR1, CCR10, CXCR1, CXCR2, and CXCR3. J. Invest. Dermatol. 132, 216–225. https://doi.org/10.1038/jid.2011.245.

Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H., and Tomic-Canic, M. (2006). Perspective article: growth factors and cytokines in wound healing. Wound Repair Regen. 14, 585–601. https://doi.org/10.1111/j.1524-475x.2006.00410.x.

Pastar, I., Stojadinovic, O., Yin, N.C., Ramirez, H., Nusbaum, A.G., Sawaya, A., Patel, S.B., Khalid, L., Isseroff, R.R., and Tomic-Canic, M. (2014). Epithelialization in wound healing: a comprehensive review. Adv. Wound Care 3, 445–464. https://doi.org/10.1089/wound.2013.0473.

Raja, R., Sivamani, K., Garcia, M.S., and Isseroff, R.R. (2007). Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front. Biosci. J. Virtual Libr. 12, 2849–2868. https://doi.org/10.2741/2277.

Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682. https://doi.org/10.1038/nmeth.2019.

Roy, S., Santra, S., Das, A., Dixith, S., Sinha, M., Ghatak, S., Ghosh, N., Banerjee, P., Khanna, S., Mathew-Steiner, S., et al. (2020). Staphylococcus aureus biofilm infection compromises wound healing by causing deficiencies in granulation tissue collagen. Ann. Surg. 271, 1174–1185. https://doi.org/10.1097/sla.0000000000003353.

El Masry, M.S., Chaffee, S., Das Ghatak, P., Mathew-Steiner, S.S., Das, A., Higuita-Castro, N., Roy, S., Anani, R.A., and Sen, C.K. (2019). Stabilized collagen matrix dressing improves wound macrophage function and epithelialization. FASEB J. 33, 2144–2155. https://doi.org/10.1096/fj.20180352r.

Zhou, X., Brown, B.A., Siegel, A.P., El Masry, M.S., Zeng, X., Song, W., Das, A., Khandelwal, P., Clark, A., Singh, K., et al. (2020). Exosome-mediated crosstalk between keratinocytes and macrophages in cutaneous wound healing. ACS Nano 14, 12732–12748. https://doi.org/10.1021/acs.nanolett.0c03064.

Cory, G. (2011). Scratch-wound assay. Methods Mol. Biol. Clifton NJ 769, 25–30. https://doi.org/10.1007/978-1-61779-207-6_2.
# STAR METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| mouse monoclonal anti-k14 antibody | abcam | ab9220 |
| rabbit monoclonal anti-Ki67 antibody | abcam | ab16667 |
| Bacterial and virus strains |        |            |
| *Pseudomonas aeruginosa* PAO1 | Obtained from collaborator Patrick Secor | NA |
| Biological samples  |        |            |
| Human wounds        | Stanford Advanced Wound Care Center | NA |
| Chemicals, peptides, and recombinant proteins |        |            |
| RPMI                | HyClone | Cat. No. SH30027.01 |
| DMEM                | HyClone | Cat. No. SH30243.01 |
| D(N)ase I           | Roche | Cat. No. 4716728001 |
| Benzonase           | Novagen | Cat No. 70746 |
| RNase A             | Thermo Fisher Scientific | No. EN0531 |
| Betadine            | Purdue Fredick Company | Cat. No. 19-065534 |
| Resazurin           | Fisher | AC18990005 |
| buprenorphine       | Zoopharm Pharmacy | na |
| LPS-EB Ultrapure from *E. coli* O111:B4 | Invitrogen | Cat: tlrl-3pelps |
| CXCL1               | Peprotech | Cat no 250-11 |
| Critical commercial assays |        |            |
| CytoTox             | Promega | G1780 |
| HaCaT human keratinocyte | AddexBio | Cat. No. T0020001 |
| hTERT Lung Fibroblast | ATCC | CRL-4058 |
| Experimental models: Organisms/strains |        |            |
| C57BL/6J            | The Jackson Laboratory | 000664 |
| Domestic Yorkshire/landrace pigs | NA | NA |
| Oligonucleotides    |        |            |
| PA0717 F TTCCCGCGTGGAGATGC | This paper | Na |
| PA0717 R CGGAGAGACGGCCACCAA | This paper | Na |
| PA0717 probe AACGCTGCGGCTGAAG | This paper | Na |
| rplU F CAAGGTCCGACCATCAAGTT | This paper | Na |
| rplU R GGCCTGAGGTGCATGTCATG | This paper | Na |
| rplU probe CGCCGTCGAAGC | This paper | Na |
| Pf4 F GGAGGAGCGGGGATGAA | This paper | Na |
| Pf4 R GGAGGAGCGACGATGAA | This paper | Na |
| Pf4 probe CAATTGCAGGCTGGTGA | This paper | Na |
| Software and algorithms |        |            |
| GraphPad Prism      | GraphPad Software | NA |

## RESOURCE AVAILABILITY

### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Paul L. Bollyky (pbollyky@stanford.edu).
Materials availability
This study did not generate new unique agents.

Data and code availability
- All data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Bacterial strains and culture conditions
P. aeruginosa strain PAO1 was used for all experiments. Isogenic phage-free strain PAO1ΔPφ4 is derived from strain PAO1 with a complete knockout of Pφ4 phage entirely (Rice et al., 2009). In general, bacteria were prepared as follows. Frozen glycerol stocks were streaked on Luria-Bertani (LB) agar and grown overnight at 37°C. An isolated colony was picked and grown overnight at 37°C in LB medium, pH 7.4 under shaking, aerobic conditions. The next day, cultures were diluted to OD600 = 0.05 in 75 mL LB media and cultures were grown until early exponential phase (OD600 ± 0.3). OD600 was measured and the required number of bacteria was calculated, washed, and prepared as described in the experiments.

Cell culture conditions
HaCaT human keratinocyte cell line (AddexBio, Cat. No. T0020001) was cultured in DMEM with 10% FBS, 100 IU penicillin, and 100 μg/mL streptomycin in T-75 flasks (Corning, Cat. No. 430641). All cells were cultured on sterile tissue culture- treated plates (Falcon). Cells were cultured at 37°C, 5% CO2 at a 90% humidified atmosphere.

Animal studies
Mice were bred and maintained under specific pathogen-free conditions, with free access to food and water, in the vivarium at Stanford University. Male mice between 10-12 weeks of age were used in this study. All mice used for in vivo infection experiments were littermates. Conventional C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All experiments and animal use procedures were approved by the Institutional Animal Care & Use Committee at the School of Medicine at Stanford University. Domestic Yorkshire/landrace cross pigs were purchased from Oak Hill genetics and housed in the vivarium at Indiana University with free access to food and water. Female pigs between 3-4 months of age and 70-80lb were used in wound studies. Before performing the experiment, the pigs are housed in compatible pairs or groups and left to acclimatize for at least 3 days. Pigs were housed individually after wounding to limit dressing and wound manipulation that may interfere with the healing process. To assure that the animals are socially housed, they are put together in the same room which will allow the visual and auditory contacts with the other pigs. All pig experiments were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee (SoM-IACUC) under protocol 18048.

Collection of wound swabs from human patients
From 06/2016 to 06/2018, patients visiting the Stanford Advanced Wound Care Center (AWCC) in Redwood City, California with open wounds were swabbed in duplicate over a one square inch area using Levine’s technique, using nylon-flocked wet swabs (Copan Diagnostics, Cat. No. 23-600- 963). Swabs were collected in PBS and stored in −80°C before transport on dry ice. In the laboratory, the swabs in PBS were thawed, vortexed vigorously for 15 seconds, and the contents were aliquoted for quantitation of Pa rplU gene and Pφ prophage gene PAO717, as detailed below. Patients at the Wound Care Center were also swabbed for confirmation by diagnostic laboratory culture for the presence of Pa. Patients were subsequently followed until wounds completely healed or until August 2018. Patients were considered Pa-positive if their swabs had detectable Pa rplU and their diagnostic cultures were positive. Patients were considered Pφ phage-positive if both duplicate wound swabs had detectable levels of Pφ phage genes. None of the Pa-negative patients had detectable Pφ phage. For patients with multiple wounds, the dominant wound was selected for analysis. Patient enrollment and swab collection were done as compliance with the Stanford University Institutional Review Board for Human Research. Written informed consent was obtained from each patient before swab collection. Details regarding patient age, gender and ethnicity can be found in Table S1.

Human wound closure analysis
Length, width, and depth measurements of the wounds were taken and recorded into the patient’s flowsheet at the start of each visit by the intake nurse. Additional measurements of undermining and tunneling were also taken when applicable. Wound measurements were taken for all patients in the study each time they visited the Stanford Advanced Wound Care Center (AWCC). The AWCC nursing staff is trained in collecting and recording the longest length, width, and depth for each wound. Total volume was calculated for each wound for analysis. Wound healing was defined as a reduction in size compared to the first recorded measurement, whereas wound size increase was defined as an increase in wound volume compared to the first recorded measurement. Informed consent was
obtained from patients before images were taken. Patient data was collected from electron medical records (EMR), including patient age, gender, co-morbidities, wound age, and other variables. This included history and physicals, progress notes, and documents uploaded into the EMR, such as the AWCC patient intake questionnaire. Patient flowsheet review was accessed for precise wound measurements and laboratory results were accessed to assess renal function and glycemic control. Microbiologic data were reviewed for antibiotic resistance profiles.

**METHOD DETAILS**

**Materials and reagents**
The following chemicals, antibiotics, and reagents were used: RPMI (HyClone, Cat. No. SH30027.01); DMEM (HyClone, Cat. No. SH30243.01); PBS (Corning Cellgro, Cat. No. 21-040-CV); tryptone (Fluka Analytical, Cat. No. T7293); sodium chloride (Acros Organics, Cat. No. 7647-14-5); yeast extract (Boston BioProducts, Cat. No. P-950); agar (Fisher BioReagents, Cat. No. BP9744); gentamicin (Amresco, Cat. No. E737).

**Preparation of heat-killed bacteria**
Frozen glycerol stocks were streaked on LB agar as described above. Individual colonies were grown in 5 mL of LB broth the next day for 2 hours to approximately 2 × 10^8 CFU/mL. The bacterial cultures were centrifuged at 6,000 × g for 5 minutes, and the pellet was washed in 1 mL of PBS three times. Finally, the pellet was resuspended in 1 mL of PBS and heated for 30 minutes at 90°C under shaking conditions. The preparation was checked for sterility by plating.

**Phage purification**
This was performed as previously reported (Sweere et al., 2019b). In brief, phages were purified by PEG precipitation only unless noted otherwise. Bacteria were infected with stocks of Pf4 phage at mid-log phase and cultured in 75 mL of LB broth for 48 hours at 37°C under shaking conditions. Bacteria were removed by centrifugation at 6,000 × g for 5 minutes, and supernatant was treated with 1 μg/mL DNase I (Roche, Cat. No. 4716728001) for 2 hours at 37°C before sterilization by vacuum filtration through a 0.22 μM filter. In some experiments, supernatant was treated with 250 μg/mL of RNAse A (Thermo Fisher Scientific, Cat. No. EN0531) or 85 U/mL of benzonase (Novagen, Cat. No. 70746) for 4 hours at 37°C before sterilization. Pf phage were precipitated from the supernatant by adding 0.5 M NaCl and 4% polyethylene glycol (PEG) 8000 (Milipore Sigma, Cat. No. P2139). Phage solutions were incubated overnight at 4°C. Phage were pelleted by centrifugation at 13,000 × g for 20 minutes, and the pellet suspended in sterile TE buffer (pH 8.0). The suspension was centrifuged for 15,000 × g for 20 minutes, and the supernatant was subjected to another round of PEG precipitation. The purified phage pellets were suspended in sterile PBS and dialyzed in 10- kDa molecular weight cut-off tubing buffer (pH 8.0). The suspension was centrifuged for 15,000 × g for 2 hours to approximately 2 × 10^8 Pf4/mL. The bacterial cultures were centrifuged at 8,000 × g for 5 minutes, and the pellet was washed in 1 mL of PBS three times. Finally, the pellet was resuspended in 1 mL of PBS and heated for 30 minutes at 90°C under shaking conditions. The preparation was checked for sterility by plating.

**Quantification of Pf phage**
As several factors can produce plaques on bacterial lawns (other species of phage, pyocins, host defensins, etc.), we quantitated Pf phage using a qPCR assay as previously described. In brief, to quantitate Pf prophage in human or mouse wound homogenates and purified Pf phage preparations, bacterial cells and debris were removed by centrifugation at 8,000 × g for 10 minutes. Supernatants were boiled at 100°C for 20 min to denature any phage particles, releasing intact Pf phage DNA. 2 μL was used as a template in 20 μL qPCR reactions containing 10 μL SensiFAST™ Probe Hi-ROX (Bioline, Cat. No. BIO-82020), 200 nM probe, and forward and reverse primers with concentrations depending on the target. Cycling conditions were as follows: 95°C 2 min, (95°C 15 sec., 60°C 20 sec.) x 40 cycles on a StepOnePlus Real-Time PCR system (Applied Biosystems). For a standard curve, the sequence targeted by the primers and probe were inserted into a pUC57 plasmid (Genewiz) and tenfold serial dilutions of the plasmid were used in the qPCR reactions. For the human wound swabs, the primers and probe were designed to recognize PAO717, a gene conserved across the Pf phage family (F at 600 nM: TTTCCCGTGGAATGCG; R at 400 nM: CGGGAGACAGCCACCCAC; probe: AACGCTGGTTGACAGAAG; the Pa 50S ribosomal gene rplU was used to confirm Pa infection (F at 200 nM: CAAGTCTCGCATCATCAAGTT; R at 200 nM: GGCCCTGACGCTTCATGT; probe: CGCCGTCGTAAGC). For the Pf4 phage purifications, the primers and probe were designed to recognize a Pf4 phage-specific intergenic region between PAO728 and PAO729 (F at 200 nM: CAAGGTCCGCATCATCAAGTT; R at 200 nM: GGCCCTGACGCTTCATGT; probe: CGCCGTCGTAAGC). For the Pf4 phage purification preparations, levels of Pf 50S ribosomal gene rplU were measured to correct for contaminating genomic Pa DNA, but those levels were usually negligible.

**In vivo murine full-thickness wound infection model**
This was done as recently described (Sweere et al., 2019a; Sweere et al., 2019b). In brief, ten-to-twelve-week old male mice were anesthetized using 3% isoflurane, and their backs were shaved using a hair clipper and further depilated using hair removal cream (Nair). The shaved area was cleaned with sterile water and disinfected twice with Betadine (Purdue Fredrick Company, Cat.
No. 19-065534) and 70% ethanol. Mice received 0.1-0.5 mg/kg slow-release buprenorphine (Zoopharm Pharmacy) as an analgesic. Mice received two dorsal wounds by using 6-mm biopsy punches to outline the wound area, and the epidermal and dermal layer were excised using scissors. For certain experiments, as indicated in the text, a silicone ring was sutured in place around the wound. The wound area was washed with saline and covered with Tegaderm (3M, Cat. No. 1642W). Bacteria were grown as described above and diluted to 1 × 10⁷ CFU/mL in PBS. Mice were inoculated with 40 µL per wound 24 hours post-wounding, and control mice were inoculated with sterile PBS. Mice were weighed daily and given Suppical Pet Gel (Henry Schein Animal Health, Cat. No. 029908) and intraperitoneal injections of sterile saline (Hospira, Cat. No. 0409-4888-10). Upon takedown, wound beds were excised and processed for histological analysis.

**Murine wound healing analysis**

This was done as previously described (Balaji et al., 2014). In brief, using a dot ruler for standardization, images of both wounds for all mice were taken on each day from Day 1 to Day 13 post-wounding. Images were taken using Canon PowerShot Camera (item Model No. 1096C001) mounted on a fixed tripod for consistency in the height and angle at which images were taken. Using the images, wound area was measured using Fiji (Image J, National Institutes of Health) by tracing the border of the wounded area, as well as the border of a standardized dot measure. For histologic analyses, wounds were harvested, bifurcated, fixed in 10% neutral buffered formalin, and embedded in paraffin. Wound sections of 5 µm were cut from paraffin-embedded blocks. Immune cell influx, general tissue morphology, epithelial gap and granulation tissue area were measured from hematoxylin and eosin (H&E) stained sections using morphometric image analysis (Image-Pro, Media Cybernetics, Silver Spring, MD, and Metamorph, Molecular Devices, Downington, PA). Images were obtained using a Nikon Eclipse microscope, and image analysis was performed using the Nikon Elements software (Nikon Instruments, Melville, NY, USA). The percentage of CD45+ cells to the total cell infiltrate was calculated in 6 high-powered fields (HPFs, 64X) for each wound section. The HPFs were chosen just above the panniculus carnosus and were evenly distributed between the two wound epithelial margins. On a 4x edge-to-edge wound section image, epithelial gap was measured as the distance (in millimeters) between encroaching epithelial margins. The granulation tissue area was measured (in mm²) as the entire cellular region within the epithelial marginal. Any sample that did not yield reliable counting due to sample quality was excluded from the analysis for that particular variable. All scoring was done by an independent pathologist.

**Porcine full thickness burn wound model**

Domestic Yorkshire/landrace cross female pigs 3–4 months of age (70–80lb) were wounded and infected to establish chronic wound biofilm model as described previously. Before performing the experiment, the pigs were housed in compatible pairs or groups and left to acclimatize for at least 3 days. Due to the nature of the experiment and study design, after burn wounding and bandaging the animals will be housed individually to prevent bandage and wound rubbing that will interfere with the healing process. Eight full thickness burn wounds (2 × 2 inch) were made on the dorsum of pigs. On day 3 post-burn, wounds were inoculated with either PAO1, or PAO1ΔPf4 strains (CFU10⁷/mL). Wounds were followed up to 56 days post inoculation. Wounds were dressed with Tegaderm™ (3M) which was kept in place with V.A.C. drape (Owens & Minor) and then wrapped with Vetrap™ and Elastikon™ (3M). Dressings were changed weekly for the duration of the study. Digital images and trans-epidermal water loss (TEWL) was collected on day 0, day 7, day 14 and day 56 post inoculation. Biopsies were collected on days 7, 14, 28, and 56 post infection. The pigs were euthanized at day 56 post inoculation. Biopsies were collected using a 6 mm sterile disposable punch biopsy tool. Each independent porcine wound is considered as one n for the porcine wound experiments. A total of 8 pigs were used for this study. All pig experiments were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee (SoM-IACUC) under protocol 18048.

**Immunohistochemistry**

Porcine wound tissues were collected at d56 post-wounding and immunostained with k14 and ki67 as previously described. Briefly paraffin-embedded tissues were cut into 8-µm thick sections. After deparaffinization and hydration, sodium citrate (pH 6.0) antigen retrieval was performed, and sections were blocked with 10% normal goat serum at room temperature, then incubated with mouse monoclonal anti-k14 antibody (ab9220; abcam; 1:400) or rabbit monoclonal anti-Ki67 antibody (ab16667, abcam, 1:200) overnight at 4°C. The specificity of the antibodies was validated using appropriate control. The signal was visualized by subsequent incubation with fluorescence-tagged secondary antibodies (Alexa Fluor 488–tagged α-mouse, or Alexa Fluor 488–tagged α-rabbit 1:200) and nuclei counter stained with DAPI. Imaging at ×20 was done using Axio Scan.Z1, Zeiss, Germany). K14 fluorescent intensity and ki67 positive cells were analyzed using Zen software (Zen blue 3.2).

**Trans-epidermal water loss (TEWL) measurement**

DermaLab Combo™ (cyberDERM inc., Broomall, PA) was used to measure the trans-epidermal water loss from the wounds. TEWL was measured in g (m²)⁻¹ h⁻¹. Dermalab Combo consists of a main measuring unit with a computer and a probe. The TEWL probe has two hygro sensors located close to each other in a perpendicular orientation, TEWL is determined from the humidity gradient between the sensors. The probe is placed on the porcine skin/wound surface. The evaporated water released from the skin/wound is detected by the sensors in the probe and measured to provide the TEWL value.
Migration assay

For HaCaT cell migration assays a standard scratch assay was used. In brief, cells were seeded at a density of $1 \times 10^6$ cells per well in DMEM 10% FBS in collagen-coated 6-well tissue culture plates. Media was removed and HaCaT cells were then serum starved in DMEM containing only 2% FBS for 24 hours prior to the treatment. A scratch defect was created in the cell monolayer along the diameter in each group using a sterile pipette tip (200 μL tip). Treatment groups included Pf4 bacteriophage with final concentration of $1 \times 10^{10}$ copy/mL and/or LPS 1 μg/ml (LPS-EB Ultrapure from *E. coli* O111:B4 purchased from Invitrogen, Cat: tlrl-3pelps). For supplementation studies, HaCaT cells were treated with CXCL1 (Peprotech, Cat no 250-11) at a final concentration of 1μg/mL in addition to Pf4 or LPS described as above. Photographic images were obtained at 0 and 24-48 hours incubation using an Invitrogen EVOS FL Imaging System. The unfilled scratch defect area was measured at each reference point per well. Data was presented as extent of wound closure, that is, the percentage by which the scratch area has decreased at a given time point for each treatment as compared to the original defect (at 0 hours). All experiments were carried out at minimum in triplicate and the passage number was similar amongst the different groups.

Lactate dehydrogenase and resazurin assays

HaCaT human keratinocyte and hTERT Lung Fibroblast (ATCC CRL-4058) cell lines were seeded at a density of $1 \times 10^4$ cells per well in 96-well tissue culture plates, 24 hours prior to treatment. Cells were treated with Pf4 bacteriophage or LPS with final concentrations ranging from $1 \times 10^8$ PFU/mL to $1 \times 10^{11}$ PFU/mL or 1 ng/mL to 1μg/ml, respectively, for 24 hours at 37°C and 5% CO₂. LPS-EB Ultrapure from *E. coli* O111:B4 was purchased from Invitrogen (Cat: tlrl-3pelps). All experiments were performed in triplicates.

Cytotoxicity, as measured by lactate dehydrogenase (LDH) release, was determined from cell-free supernatants using the CytoTox kit according to the manufacturer’s protocol (Promega, G1780). Percent Cytotoxicity was calculated as follows:

$$\text{% Cytotoxicity} = \frac{\text{Experimental} - \text{Untreated cells}}{\text{Lysed cells} - \text{Untreated cells}} \times 100$$

The proliferation of HaCaT and hTERT lung fibroblast cells was determined using the resazurin assay. Resazurin (Fisher Sci, AC18990005) was added to the cells 24 hours after Pf4 or LPS treatment and incubated for ~1 hour at 37°C and 5% CO₂ before fluorescence measurement. The oxidized non-fluorescent blue resazurin reduces to a red fluorescent dye (resorufin) by the mitochondrial respiratory chain in live cells. The number of living cells is directly proportional to the amount of resorufin produced. A microplate reader was used to determine resorufin fluorescence (Excitation: 551nm, Emission: 596nm).

Luminex immunoassay

HaCaT cells were seeded at $1 \times 10^6$ cells per well in DMEM 10% FBS in collagen-coated 6-well tissue culture plates. Media was removed and HaCaT cells were then serum starved in DMEM containing only 2% FBS for 24 hours prior to the treatment. Cells were treated with Pf4 ($1 \times 10^{10}$ copies/ml) and/or LPS (1 μg/mL). Supernatant was collected at 24 and 48hrs and used for cytokine profiling through Luminex (The Human Immune Monitoring Center, Stanford). Human 63-plex kits were purchased from eBiosciences/Affymetrix and used according to the manufacturer’s recommendations with modifications as described below. Briefly: Beads were added to a 96 well plate and washed in a Biotek ELx405 washer. Samples were added to the plate containing the mixed antibody-linked beads and incubated at room temperature for 1 hour followed by overnight incubation at 4°C on an orbital shaker at 500-600 rpm. Following the overnight incubation plates were washed in a Biotek ELx405 washer and then biotinylated detection antibody added for 75 minutes at room temperature with shaking. Plate was washed as above and streptavidin-PE was added. After incubation for 30 minutes at room temperature wash was performed as above and reading buffer was added to the wells. Each sample was measured in duplicate. Plates were read using a Luminex 200 instrument with a lower bound of 50 beads per sample per cytokine. Custom assay Control beads by Radix Biosolutions are added to all wells.

QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analyses were done using GraphPad Prism (GraphPad Software, Inc. La Jolla, CA). All Unpaired T-Tests, Mann-Whitney Test, Fisher’s Exact Tests, and Chi-Square Test were two-tailed. Depicted are Means with Standard Error or Standard Deviation of the population unless otherwise stated. Statistical significance was considered $p<0.05$. Statistical details are included in figure legends.